Xiao ST, Kuang CY. Endothelial progenitor cells and coronary artery disease: Current concepts and future research directions. World J Clin Cases 2021; 9(30): 8953-8966 [PMID: 34786379 DOI: 10.12998/wjcc.v9.i30.8953]
Corresponding Author of This Article
Chun-Yan Kuang, MD, PhD, Chief Physician, Department of Cardiovascular Diseases, Guizhou Provincial People's Hospital, No. 83 Zhongshan East Road, Guiyang 550003, Guizhou Province, China. xiaokcy@sina.com
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Oct 26, 2021; 9(30): 8953-8966 Published online Oct 26, 2021. doi: 10.12998/wjcc.v9.i30.8953
Endothelial progenitor cells and coronary artery disease: Current concepts and future research directions
Sen-Tong Xiao, Chun-Yan Kuang
Sen-Tong Xiao, Department of Cardiovascular Diseases, People’s Hospital Affiliated to Guizhou Medical University, Guiyang 550003, Guizhou Province, China
Chun-Yan Kuang, Department of Cardiovascular Diseases, Guizhou Provincial People's Hospital, Guiyang 550003, Guizhou Province, China
Author contributions: Xiao ST wrote the manuscript; Kuang CY revised the article.
Supported bythe Guizhou Science and Technology Department, No. Qian-Ke-He [2018]1097; the National Natural Science Foundation of China, No. 81560056; Program for Training Outstanding Young Scientific and Technological Talents of Guizhou Province, No. Qian Kehe Platform Talents [2019]5662; Program for the Scientific Activities of Selected Returned Overseas Professionals in Guizhou Province, No. Grant Qian-Ren [2018]0003; and Scientific and Technological Platform and Talent Team Project of Guizhou Province, No. Qian Kehe Platform Talents [2017]5405.
Conflict-of-interest statement: The authors report that they have no conflicting interests.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chun-Yan Kuang, MD, PhD, Chief Physician, Department of Cardiovascular Diseases, Guizhou Provincial People's Hospital, No. 83 Zhongshan East Road, Guiyang 550003, Guizhou Province, China. xiaokcy@sina.com
Received: March 26, 2021 Peer-review started: March 26, 2021 First decision: May 12, 2021 Revised: May 12, 2021 Accepted: August 18, 2021 Article in press: August 18, 2021 Published online: October 26, 2021 Processing time: 208 Days and 14.6 Hours
Abstract
Vascular injury is a frequent pathology in coronary artery disease. To repair the vasculature, scientists have found that endothelial progenitor cells (EPCs) have excellent properties associated with angiogenesis. Over time, research on EPCs has made encouraging progress regardless of pathology or clinical technology. This review focuses on the origins and cell markers of EPCs, and the connection between EPCs and coronary artery disease. In addition, we summarized various studies of EPC-capturing stents and EPC infusion therapy, and aim to learn from past technology to predict the future.
Core Tip: The development of clinical applications of endothelial progenitor cells (EPCs) has progressed in recent decades. In this review, we summarize and discuss the origins and antibody markers of EPCs and the clinical effects of EPC stents and infusion. We hope to predict future clinical uses of EPCs.
